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Vitamin D3 repletion versus placebo as
adjunctive treatment of heart failure
patient quality of life and hormonal indices:
a randomized, double-blind, placebo-
controlled trial
Heidi D. Moretti1* , Vincent J. Colucci2,3 and Bradley D. Berry1,2
Abstract
Background: Vitamin D status may influence heart failure (HF) patient outcomes by affecting b-type natriuretic
peptide (BNP), parathyroid hormone (PTH), and enhancing cardiac contractility. Vitamin D deficiency is associated
with morbidity and mortality in HF patients. The objective of this study was to determine if vitamin D3 at a
comparatively high dose would replete 25-hydroxyvitamin D (25(OH)D) stores, improve BNP, PTH, cardiopulmonary
function, reduce inflammatory markers, and improve quality of life (QOL) in HF patients.
Methods: This was a 6 month, parallel group, double-blind, placebo-controlled, single clinic center, randomized
trial of supplemental vitamin D3 using a dose of 10,000 IU daily or placebo in 40 vitamin D deficient or insufficient
(25(OH)D level ≤ 32 ng/ml) patients with stable New York Heart Association Class II-III HF in a specialty cardiology
clinic. All variables were measured at baseline and 6 months. Values between the two treatment groups were
assessed using Student’s t-test or Mann-Whitney Test. Univariate analysis of covariance was conducted to adjust for
variance in baseline 25(OH)D.
Results: All results were adjusted for baseline 25(OH)D. The change in BNP from baseline was Δ +30 ± 950 pg/ml
for treatment vs. placebo Δ +400 ± 1900 pg/ml, p = 0.003. 25(OH)D serum levels rose by 49 ± 32 ng/ml in the
treatment group vs 4 ± 10 ng/ml in the placebo group, p < 0.001. PTH and exercise chronotropic response index
improved in the treatment group vs placebo group, respectively, but both were attenuated by adjustment
((Δ-20 ± 20 pg/ml vs Δ + 7 ± 53 pg/ml respectively (p = 0.01, adjusted p = 0.07)) and (Δ + 0.13 ± 0.26 vs. Δ-0.
03 ± 02.9 respectively, p < 0.01, adjusted p = 0.17)). Other measured cardiopulmonary parameters remained
unchanged. High sensitivity C-reactive protein (hsCRP) remained unchanged for women, but improved for men
(Δ-2 ± 4 treatment versus Δ2 ± 5 mg/L placebo, p = 0.05). QOL scores, including composite overall and clinical
summary scores significantly improved in treatment compared to placebo (Δ + 10 ± 15 versus −6 ± 15, p < 0.01
and Δ + 8 ± 14 versus −8 ± 18, p = 0.01, respectively).
Conclusions: Repletion of 25(OH)D may improve QOL in HF patients and may help to normalize BNP, PTH, and
hsCRP.
Trial registration: Clinicaltrials.gov, Trial Registration Number: NCT01636570, First registered 3 July 2012.
Keywords: Vitamin D, Heart failure, B-type natriuretic peptide, Parathyroid hormone, Inflammation, C-reactive
protein, Quality of life, 25-hydroxyvitamin D, Calcitriol
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Background
Current lifetime risk for developing heart failure is esti-
mated to be at 20–46% for people aged 45 and older in
the United States [1], with a prevalence of the disease at
approximately 23 million people worldwide [2]. Heart
failure is a significant burden on the healthcare system,
costing over 32 billion dollars per year with high risks of
morbidity and mortality [3]. Data are accumulating to
suggest that vitamin D, a secosteroid hormone, may
modify disease course in numerous conditions, including
heart failure [4–7]. Patients with both heart failure and
vitamin D deficiency have an exceedingly high risk of
morbidity and mortality, including sudden cardiac death
[6, 8]. It is therefore important to assess if supplementa-
tion with the intent of achieving adequate circulating
vitamin D levels also results in improved hormonal and
inflammatory markers and patient health-related quality
of life outcomes (QOL) in heart failure.
Vitamin D deficiency appears to be prevalent in sub-
sets of patients with heart failure, including elderly pa-
tients at high northern latitudes or patients with
concomitant kidney disease [8, 9]. Preliminary data sug-
gests that vitamin D may improve ejection fraction (EF)
[7, 10–12], and it appears that achieving a serum 25-
hydroxyvitamin D (25(OH)D) level of greater than 40–
50 ng/ml may be the threshold for benefit in heart
failure patients [10]. Vitamin D may help resolve cases
of hypocalcemic cardiomyopathy as shown in case re-
ports of pediatric cardiomyopathy and heart failure re-
lated to rickets [13, 14]. This is a rare condition,
therefore, extrapolating these data to the adult HF popu-
lation would be inaccurate so inferences can’t necessarily
be made for the adult heart failure population.
Results of vitamin D supplement trials are not consist-
ent across all studies, but this is perhaps due to hetero-
geneity in study design, dosing regimens, and biological
flaws [15, 16]. These biological flaws may be overlooked
when evaluating the research for vitamin D. Further, bio-
logical flaws are created when the design does not in-
clude evaluation vitamin D status, use pulse dosing, or
the dose of vitamin D is not sufficient to change serum
vitamin D status. Frequently, these flaws can lead to null
results [14–16].
There is also a gap in the literature related to vitamin
D and functional outcomes such as health-related QOL
and exercise cardiopulmonary status (CPX) in heart fail-
ure patients. QOL and CPX are strong prognostic
markers of morbidity and mortality [17, 18]. Vitamin D
is directly involved in the calcium-related contractility in
the heart. Cardiomyocytes and vascular smooth muscle
cells possess both vitamin D receptors and calcitriol-
dependent calcium binding proteins [19, 20]. The pres-
ence of both vitamin D receptor and 1,25-dihydroxyvita-
min D[1,25(OH)2D]calcitriol-dependent calcium binding
proteins in these tissues allows for the onsite conversion
of 25(OH)D to calcitriol 1,25(OH)2D and calcium-
dependent cellular processes, underscoring the require-
ment of vitamin D in these tissues. Depletion of vitamin
D3 in the rat model results in impaired contractile func-
tion as well. [21]. Therefore, the aim of the current study
is unique as we sought to determine if vitamin D3 in
higher doses would result in sufficient circulating 25-
hydroxyvitamin D levels, and subsequently result in
changes in surrogate markers of heart failure outcomes.
Methods
We aimed to evaluate the effects of vitamin D on hor-
monal markers, functional outcomes, and QOL in our
center. Therefore, we hypothesized that vitamin D3 at
10,000 IU daily would be sufficient to replete 25(OH)D
stores over a 6-month period, and reduce or normalize
b-type natriuretic peptide (BNP), our primary outcome
measure. Our secondary outcome measures included
changes in or improvement of parathyroid hormone
(PTH), high sensitivity c-reactive protein (hsCRP), QOL,
and cardiopulmonary function using CPX.
Study design
This was a single center, parallel group, randomized,
controlled, double–blinded prospective trial. Enrollment
and all assessment were conducted at a specialty heart
failure clinic by cardiologists, in Western Montana be-
tween fall of 2012 and spring of 2015. Clinic patients
with New York Heart Association (NYHA) Class II or
III heart failure were eligible for inclusion into the study
if they were 18 years or older, had been on stable and
guideline directed medical therapy (GDMT) for greater
than 3 months, and had a 25(OH)D level of ≤32 ng/ml.
Patients who were pregnant, breastfeeding, or with any
clinically unstable medical disorder were excluded. All
data, including QOL, laboratory values, and cardiopul-
monary function were collected from the clinic by re-
search coordinators and nursing staff. Patients currently
taking ≤1000 IU vitamin D daily could enroll in the trial.
Randomization was computerized in a permuted block
size of 4 and occurred off-site at a university pharmacy
department. Vitamin D3 and placebo bottles were given
sequentially numbered identical containers and adminis-
tered serially. The trialists, patients, and caregivers were
blinded to the randomization until all data were col-
lected and collated. Patients were excluded from the trial
if they presented with any of the following conditions:
hypercalcemia, nephrolithiasis, sarcoidosis, acute decom-
pensation of heart failure, and/or any clinically unstable
systemic medical disorder, including severe pulmonary
disease. Vitamin D3 has been shown to be safe long-
term at doses of 10,000 IU per day [22]. Vitamin D dose
at a given amount seems to result in a plateau in 25
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(OH)D at or around 1 month, so we estimated that
6 months of dosing would be sufficient to have an effect
on hormonal and cardiopulmonary status [22]. All pa-
tients provided written, informed consent and the trial
was approved by the Providence Saint Patrick Hospital
Institutional Review Board. Patient variables were di-
vided into gender differences for men and women. Vita-
min D3 at 10,000 IU per day (Biotech Pharmacal,
Fayetteville, AR) or identical placebo (dextrose) was
given in parallel design. Patients remained on all current
medications as prescribed, and changes in any baseline
medication dosages or forms were recorded. All patients
enrolled in the study were receiving best tolerated and
GDMT, which included Angiotensin Converting Enzyme
Inhibitor (ACE), Angiotensin Receptor Blocker (ARB),
beta blockers (Table 1), and aldosterone antagonists.
They were also receiving statins and loop and/or non-
loop diuretics as indicated. All medications had been
stable for at least 3 months before enrollment.
Patients were evaluated at baseline and at 6 months
for all clinical and laboratory data, and they had
complete medical assessments, QOL, and CPX tests at
both visits. At 3 months, both 25(OH)D and serum cal-
cium levels were drawn. Due to the high number of pa-
tients screened taking vitamin D at 1000 IU daily that
remained deficient in 25(OH)D, we modified the proto-
col to include patients who were taking up to 2000 IU
per day of vitamin D prior to enrollment that had base-
line levels of 25(OH)D ≤ 32 ng/ml. If 25-hydroxyvitamin
D levels exceeded 150 ng/ml or calcium level exceeded
10.5 mg/dl at 3 months, vitamin D3 dose was decreased
to 5000 IU per day. If any adverse effects were observed
by the patient or cardiologist, the patient was withdrawn
from the trial.
Laboratory parameters
BNP, PTH, hsCRP, and 25(OH)D, hsCRP, complete
metabolic panels and complete blood counts were all
measured using commercially available kits.
QOL
The Kansas City Cardiomyopathy (KCCQ), a validated
tool that is both sensitive and specific for assessment of
change in health-related QOL, was interviewer adminis-
tered at baseline and at 6 months of treatment [23].
Briefly, the KCCQ has domains of physical function,
symptom frequency and severity, social function and
QOL; composite scores are derived from these domains.
Scores are computed for a range of 0–100 for each do-
main, in which higher scores reflect better health status.
CPX
All subjects, following 2 min of rest, completed an initial
1-min, constant-rate stair step. After the initial work-
load, speed and grade were incrementally increased at 1-
min intervals to peak attained exertion. Ventilatory ex-
pired gas analysis was collected at rest and throughout
exercise using a miniaturized metabolic cart (Shape HF
cardiopulmonary testing system, St. Paul, MN). The
Shape analyzer was self-calibrated daily using an auto-
Table 1 Baseline Demographics
All Groups Placebo Treatment P-value
Age (years) 67 ± 14 65 ± 16 67 ± 11 0.53
Gender (n, % Female) 13/40 (33%) 6/20 (30%) 7/20 (35%) 0.74
Race (n, % Caucasian) 38/40 (95%) 19/20 (95%) 19/20(95%) 1
BMI (kg/m2−) 29 ± 5 28 ± 5 31 ± 5 0.33
HR (BPM) 72 ± 11 70 ± 10 74 ± 11 0.92
Systolic BP (mmHg) 113 ± 16 117 ± 19 110 ± 14 0.38
Diastolic BP (mmHg) 69 ± 10 71 ± 10 67 ± 10 0.42
EF (%) 28 ± 9 30 ± 11 27 ± 7 0.13
Ischemic (#, %) 25/40 (63%) 14/20 (70%) 11/20 (55%) 0.33
Nonischemic (#, %) 15/40 (37%) 6/20(30%) 9/20 (45%) 0.33
ACE/ARB (#, %) 33/40 (83%) 17/20 (85%) 16/20 (80%) 0.68
Digoxin (#, %) 4/40 (10%) 2/20 (10%) 2/20 (10%) 1
Beta Blocker (#, %) 32/40 (80%) 14/20 (70%) 18/20 (90%) 0.11
Loop Diuretic (#, %) 28/40 (70%) 13/20 (65%) 15/20 (75%) 0.49
Spironolactone and/or Eplerenone 31/40 (78%) 16/20 (80%) 15/20 (75%) 0.70
Statins (#, %) 29/40 (73%) 15/20 (75%) 14/20 (70%) 0.72
Data are expressed as mean ± standard deviation (SD) or number and percentages. Abbreviations: Body Mass Index (BMI), Heart Rate (HR), Blood Pressure (BP),
Ejection Fraction (EF) Angiotensin Converting Enzyme Inhibitor (ACE), Angiotensin Receptor Blocker (ARB)
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cal performance test. Heart rhythm was assessed on a 4-
lead electrocardiogram, and arterial O2 saturation was
monitored with finger pulse-oximetry (Envitec D-23966,
Wismar, Germany).
Minute ventilation, the end-tidal partial pressures of
O2 (PETO2) and CO2 (PETCO2), oxygen consumption
(VO2), and carbon dioxide production (VCO2) was ac-
quired breath by breath and averaged over 30-s intervals
every minute until exhaustion (progressive exercise to
peak oxygen consumption, VO2peak). The data points
between the averaged value during the first 30 s of the
initial work load and at peak exercise was used to calcu-
late the ventilator efficiency (VE) to VCO2 slope and
changes in partial pressure end-tidal CO2. In addition,
the chronotropic response index (CRI) and O2 uptake
efficiency slopes were determined during exercise as pre-
viously described [24]. Greater values of oxygen uptake
efficiency slope indicate a higher ventilatory efficiency,
and a larger CRI slope is an indicator of improved heart
rate reserve.
Statistical analysis
We set a threshold of 90% power to detect a between-
group difference in BNP (based on 74 ± 25 pg/ml
between-group differences seen in the literature) to de-
termine a need for at least 6 patients in each [25]. The
differences between the means of the two data sets were
assessed by 2-sided independent samples t test. For data
not normally distributed, the analysis was performed by
means of Wilcoxon signed-rank test. A p-value of 0.05
or less was considered statistically significant. For the
study to have >90% power to detect a between-group
difference for our primary outcome measure of BNP of
74 pg/ml with SD value of 25 mg/ml found in the litera-
ture, the number of patients in the participating group
must be 6 or more [25]. A two-tailed z-value related to
α = 0.05and a two-tailed z-value related to β = 0.1 were
used for the estimate together with the expectation that
vitamin D3 supplementation would lead to a reduction
in BNP.
We increased our goal recruitment size to 20 per
group to allow for gender differences to be assessed.
Data presented was analyzed using SPSS version 23
(IBM® Corporation, Armonk, New York), and expressed
as the mean ± standard deviation (SD). Normality was
assessed for each variable by the Shapiro Wilk test.
Values between the two treatment groups were assessed
using Student’s t-test or Mann-Whitney Test for nor-
mally distributed and non-normally distributed data, re-
spectively. Univariate analysis of covariance was
conducted to adjust for variance in baseline vitamin D
status. Significance was set a priori at α = 0.05. Other
continuous variables (expressed as means, SD) and cat-
egorical variables (expressed as frequencies) were
collected during the study to characterize the group.
Subgroup analysis was conducted for gender differences
for all outcome variables. Differences in race could not
be conducted due to the patient demographic of the re-
gion was primarily white. Data were analyzed per proto-
col analysis. All data is available in the attached data
repository (Additional file 1). The CONSORT checklist
is attached in Additional file 2.
Results
A total of 40 patients were enrolled into the study
(Fig. 1). Of these, 2 dropped out for unrelated reasons (1
treatment, 1 placebo), and 2 patients did not complete
the vitamin D3 supplementation (both in the treatment
group, not related to intolerance, but related to compli-
ance). A total of 17 pts. had completed the study in the
treatment group, and 19 in the placebo group. Baseline
characteristics were similar between both groups for all
parameters measured (see Table 1). Additionally, all la-
boratory parameters were similar between the groups at
baseline, with the exception of PTH (p = 0.002, Table 2).
All patients tolerated the vitamin D3 treatment or pla-
cebo, and no patients were required to have a reduction
in dosage or discontinuation of treatment.
At 3 months, calcium levels were unchanged from
baseline in both groups (8.9 ± 0.6 mg/dl in the placebo
group and 9.0 ± 0.3 mg/dl in the treatment group
(Fig. 2). At 3 months, 25(OH)D levels reached an aver-
age of 60 ± 30 ng/ml in the treatment group and
remained at 20 ng/ml in the placebo group (p-value be-
tween groups of <0.001). By 6 months, vitamin D status
rose to 70 ± 28 ng/ml in the treatment group while the
placebo group remained unchanged (20 ± 7 ng/ml).
All results were adjusted for baseline 25(OH)D. In a total
of 17 patients, BNP improved in the treatment group,
Δ + 30 ± 950 pg/ml, compared to the placebo group of 19
patients, Δ + 400 ± 1900 pg/ml (p = 0.002) (Table 3). After
adjustment for baseline 25(OH)D, the difference between
groups for BNP remained significant (p = 0.003). Serum
PTH also significantly improved (placebo Δ + 7 ± 53 pg/
ml versus treatment Δ-20 ± 20 pg/ml, p = 0.002, Fig. 3).
This difference was attenuated when adjusted for baseline
vitamin D (p = 0.07). Absolute scores for PTH were
90 ± 96 pg/ml at baseline and 93 ± 112 pg/ml at 6 months
for the placebo group versus 58 ± 28 pg/ml at baseline and
45 ± 19 pg/ml at 6 months for the treatment group (Table
2). Adjustment for baseline 25(OH)D attenuated the differ-
ence between the groups (p = 0.07). hsCRP levels were not
significantly different between the groups.
To assess in an exploratory way if inflammation af-
fected PTH response to vitamin D, a cohort of the pa-
tients with hsCRP levels greater than 1 were analyzed as
well. In this cohort, PTH was significantly improved by
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Table 2 Baseline and Post-Treatment/Placebo Laboratory Parameters
Placebo Baseline Placebo 6 months Treatment Baseline Treatment
6 months
p-value
Baseline
p-value
6 months
Sodium (mEq/L) 140 ± 2 140 ± 3 138 ± 3 139 ± 2 0.11 0.24
Chloride 104 ± 4 104 ± 3 99 ± 21 104 ± 3 0.25 0.25
Co2 26.3 ± 2.9 25.8 ± 2.1 25.0 ± 3.0 25.5 ± 3.0 0.46 0.86
Potassium(mEq/L) 4.1 ± 0.8 4.1 ± 0.3 4.4 ± 0.3 4.3 ± 0.4 0.29 0.15
BUN (mg/dl) 22 ± 12 23 ± 13 24 ± 10 27 ± 13 0.46 0.33
Creatinine 1.3 ± 0.6 1.3 ± 0.6 1.2 ± 0.4 1.3 ± 0.5 0.29 0.86
Glucose (mg/dl) 115 ± 41 105 ± 36 118 ± 35 108 ± 23 0.64 0.79
Calcium (mg/dl) 8.9 ± 0.5 8.9 ± 0.8 9.0 ± 0.4 9.2 ± 0.4 0.71 0.18
Hemoglobin (g/dl) 14.1 ± 1.9 13.9 ± 1.5 14 ± 6.2 13.4 ± 1.5 0.63 0.51
Hematocrit (%) 44.5 ± 12.8 41.5 ± 4.4 42.6 ± 11.0 40 ± 4.6 0.39 0.31
BNP (pg/ml) 1800 ± 400 2300 ± 950 1600 ± 550 1400 ± 600 0.43 0.31
PTH (pg/ml) 90 ± 96* 93 ± 112 58 ± 28 45 ± 19 0.002 0.002
hsCRP (mg/ml) 3.5 ± 3.1 4.4 ± 3.9 5.4 ± 5.5 3.8 ± 1.1 0.42 0.18
25(OH)D (ng/ml) 20 ± 7 20 ± 9 19 ± 7 70 ± 28 0.8 0.001
Data are expressed as mean absolute values + standard deviation (SD). Abbreviations: Blood Urea Nitrogen (BUN), B-type Natriuretic Peptide (BNP), Parathyroid
Hormone (PTH), high-sensitivity c-reactive protein (hsCRP), and 25-hydroxyvitamin D (25(OH)D)
*Indicates significant difference in PTH between placebo and treatment group at baseline, p=0.002
Fig. 1 Consort Diagram. Study Design and Enrollment
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vitamin D Δ-21 ± 20 compared to the placebo group
Δ4 ± 17 pg/ml, p = 0.005 (Fig. 3).
Parameters from CPX test remained unchanged except
for chronotropic response index (CRI) (Table 4), which
significantly improved at 6 months in the vitamin D3
group (Δ0.1 ± 2.4 treatment versus −0 ± 2.9 placebo,
p = 0.009). This was attenuated after adjustment for
baseline vitamin D (p = 0.17).
To determine within-gender differences, data were
analyzed for all the outcome measures. Changes be-
tween groups for BNP, cardiopulmonary function, and
QOL remained similar to the composite group for
most outcomes with the exception of hsCRP; for
men, hsCRP significantly improved (hsCRP Δ −2 ± 4
versus 2 ± 5 mg/L for the placebo group, p = 0.05),
but not for women (Δ1 ± 5 treatment versus 0 ± 4
for placebo, p = 0.87).
KCCQ scores significantly improved compared to pla-
cebo in the domain of physical (Δ + 9 ± 14 treatment
versus Δ-5 ± 20 placebo), QOL (Δ + 11 ± 21 treatment
versus Δ-2 ± 19 placebo), and for both the overall sum-
mary (Δ + 10 ± 15 treatment versus Δ-6 ± 15 placebo)
(Fig. 4), and the clinical summary (Δ + 9 ± 14 treatment
versus Δ-8 ± 18 placebo) (Table 3). Stability scores and
social scores did not differ significantly between the
groups. Symptom frequency scores trended towards im-
provement in the vitamin D group, and significantly im-
proved for the vitamin D group for symptom burden
(p = 0.002) (Fig. 4). Adjustment for baseline vitamin D
Fig. 2 Change in 25 hydroxyvitamin D (25(OH)D) level and calcium
level at 3 and 6 months. 25(OH)D significantly increased from baseline
in the treatment group by 3 months and 6 months compared to
placebo group, *p = 0.001. Calcium levels remain unchanged
Table 3 Changes in lab parameters and KCCQ
Vitamin D 95% CI Placebo 95% CI p-value Corrected model
p-value
BNP 30 ± 950 −10, 70 400 ± 1900 210–600 0.002* 0.003*
PTH −20 ± 20 −28, −11 7 ± 53 16, 30 <0.002* 0.07
hsCRP −1 ± 5 −3, 1 1 ± 6 −2, 4 0.18 0.21
25-(OH)D 51 ± 32 39,62 1 ± 6 −2, 3 <0.001* Na
Physical Score 9 ± 14 3,15 −5 ± 20 −4, 14 0.02* 0.07
Symptom Frequency 10 ± 28 −2, 28 −6 ± 17 −2, 13 0.03* 0.06
Symptom Burden 12 ± 20 3, 20 −7 ± 15 −14, 0 0.002* 0.05*
Total Symptom 11 ± 22 1, 22 −6 ± 17 −13, 1 0.013* 0.03*
Stability Score 3 ± 35 −13, 18 1 ± 14 −5,7 0.88 0.84
QOL Score 11 ± 21 3, 21 −2 ± 20 −11, 7 0.05* 0.11
Social Score 10 ± 24 0, 24 −4 ± 27 −16, 8 0.14 0.27
Overall Summary Score 10 ± 15 4,17 −6 ± 15 −13, 1 <0.02* 0.01*
Clinical Summary Score 8 ± 14 2, 14 −8 ± 18 −16, 0 0.02* 0.01*
Data are expressed as mean ± SD, 95% CI
Abbreviations: Kansas City Cardiomyopathy Questionnaire (KCCQ), Standard Deviation (SD), Confidence Interval (CI), B-type Natriuretic Peptide (BNP), Parathyroid
Hormone (PTH), high sensitivity c-reactive protein (hsCRP), 25 hydroxyvitamin D (25-(OH)D), Quality of Life Score (QOL)
*Indicates significant difference between groups
Fig. 3 Change in PTH from baseline at 12 weeks and 6 months.
Change in PTH is depicted on the left, and change in PTH in cohort
with hsCRP > 1 is shown in the left columns. * indicates p < 0.05
and ** indicates p < 0.01
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status slightly attenuated all scores except the overall
and clinical summary scores (Table 3).
Discussion
The conclusions from our research support prior findings
that vitamin D3 supplementation at pharmacological
doses may benefit patients with heart failure (7,10–12).
However, clinical trials using vitamin D supplementation
with hard endpoints such as cardiovascular death, hospi-
talizations, or all-cause mortality still have not yet been
conducted. So far, vitamin D supplementation guidelines
have not been included in heart failure guidelines by
Table 4 Changes in Cardiopulmonary Exercise Tests
Vitamin D Placebo p-value Corrected model p-value Vitamin D CI (lower) Vitamin D CI (higher)
Peak VO2 ml/kg/min −1.7 ± 3.4 0.4 ± 3.5 0.12 0.30 −3.2 −0.21
Peak METS −0.5 ± 1.1 −0.2 ± 0.7 0.43 0.32 −0.9 0.03
Peak Tidal Vol 30 ± 380 −40 ± 240 0.55 0.72 −132.5 195.3
CRI 0.1 ± 0.20 0 ± 2.9 0.009* 0.17 0.02 0.24
VE Slope 3.0 ± 6.7 0.8 ± 5.7 0.36 0.51 0.1 5.9
Heart Composite 0.3 ± 0.7 0.1 ± 0.6 0.32 0.57 0.28 0.36
Pulmonary Vascular Score 0.1 ± 0.5 0.1 ± 0.6 0.97 0.34 −0.1 0.4
Deconditioning Score 0.3 ± 0.6 0.2 ± 0.7 0.65 0.19 0.03 0.53
PETCO2(mmHg) −1.6 ± 3.4 −0.6 ± 1.9 0.30 0.40 −3.1 −0.11
Shape Score 0.1 ± 1.6 0.3 ± 1.0 0.65 0.71 −0.6 0.8
Peak RER 0.1 ± 0.3 −0 ± 0.1 0.26 0.44 0 0.24
OUES −0.1 ± 0.4 −0.3 ± 0.5 0.12 0.32 −0.14 0.36
Data are expressed as Δ ± SD, 95% CI)
Abbreviations: Standard Deviation (SD), Confidence Interval (CI), Volume of oxygen consumed (VO2), metabolic equivalents (METS), volume (Vol), Ventilatory
Efficiency (VE), Respiratory Exchange Ratio (RER), Oxygen Uptake Efficiency Slope (OUES)
*Using Mann-Whitney
Fig. 4 Change in Quality of Life Scores using the Kansas City Cardiomyopathy Questionnaire
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European Society of Cardiology or American College of
Cardiology (26–27). Adequate research of vitamin D
measuring sufficient repletion in a large number of pa-
tients also has not been performed.
BNP findings
Our findings demonstrate that therapeutic vitamin D3
treatment is significantly better than placebo for BNP
measures when adjusted for baseline vitamin D in pa-
tients with reduced ejection fraction heart failure. These
findings are noteworthy because BNP has been shown to
be strongly associated with recurrent hospitalization and
mortality in this patient population. BNP was the most
powerful independent marker of outcome in heart fail-
ure patients in the Valsartan Heart Failure study [26]. A
limitation to our current finding is that BNP variability
between patients was large, and our enrollment criteria
did not specify a range for BNP.
Prior research is conflicting related to vitamin D and
its influences on BNP. A study by Jiang et al. failed to
show a change in BNP after vitamin D supplementation,
but a more recent supplement trial found that vitamin D
dramatically improved BNP levels using 200,000 IU vita-
min D per week [27, 28]. However, a limitation of this
trial was a lack of randomization [28]. In the meta-
analysis failing to find a change in BNP, biological flaws
were present, as the average 25(OH)D level was not
taken into consideration. Our current study is the high-
est dose per day of any study to our knowledge. Mecha-
nisms of vitamin D3 actions related to BNP have not
been fully described, but the vitamin D receptor likely
plays a role in regulating the BNP gene promoter [29].
QOL
In our study, QOL scores improved significantly in most
domains, and this remained robust after adjustment.
Our study is the first to provide vitamin D3 at a dose
shown to replenish vitamin D stores, and also measure
QOL. Prior research demonstrates that improvement in
QOL predicts event-free survival in heart failure patients
[30]. Comparatively, current treatments don’t approach
the effect size for QOL that our study has shown. For
example, the Angiotensin-Neprilysin Inhibition
(LCZ696) versus Enalapril trial [31] demonstrated a
2.99-point worsening in KCCQ clinical summary with
the use of LCZ696, which was statistically better than
conventional therapy with Enalapril (worsened KCCQ by
4.63 points). In contrast, our KCCQ clinical summary
had an 8 point average improvement. The implications
of this could be large if replicated.
Heart failure results in diminished QOL, in part due
to frailty; vitamin D3 may help by preserving and im-
proving lean body mass and strength [32–34]. A recent
trial in heart failure patients failed to show
improvements in physical function and QOL in heart fail-
ure patients. However, serum 25(OH)D never surpassed
32 ng/ml on average [34]. Two pulse doses of vitamin D2
is likely insufficient to overcome a deficiency in heart fail-
ure [22]. In contrast, when 200,000 IU vitamin D3 per
week was given to heart failure patients, the 6-min walk
test was significantly improved from baseline [28].
CPX
While most CPX remained unchanged in our study, we
did find that vitamin D seemed to improve CRI. How-
ever, adjustment for baseline vitamin D attenuated this.
Our study may not have been long enough in duration
to find differences in cardiopulmonary exercise testing
as a whole. Our finding that chronotropic response may
be improved by vitamin D deserves further attention
since this index is inversely associated with mortality in
heart failure patients [35].
Treatment of heart failure with Angiotensin Convert-
ing Enzyme Inhibitors and Angiotensin Receptor
Blockers has been documented to improve cardiopulmo-
nary function and exercise capacity [36]. The mechanism
of action of these medications is inhibition of the Renin-
Angiotensin-Aldosterone System (RAAS), in particular,
angiotensin II. Vitamin D analogs block renin upregula-
tion and ANGII accumulation in animals [37]. Vitamin
D3 thus may also improve CPX with synergistic effects
of established treatments. Further research with vitamin
D3 and vitamin D cofactors with longer duration may
further elucidate the effects of vitamin D3 on CPX.
PTH
PTH was reduced by 20 pg/ml in our vitamin D3 group;
other studies have had similar findings in heart failure to
a lesser magnitude [38]. Adjustment for baseline
25(OHD status in our study did attenuate this signifi-
cance; however, PTH and 25(OH)D are quite inter-
related, so this does not appear to minimize our treat-
ment effect. However, our baseline PTH levels were
higher than most prior trials [39]. Vitamin D3, therefore,
may be more beneficial in patients with markedly ele-
vated PTH. Our groups were not matched at baseline in
regard to PTH. This is possibly true because our enroll-
ment criteria did not include PTH parameters for exclu-
sion or inclusion. Serum calcium also didn’t vary
between the groups, but we did not allow patients with
hypercalcemia into the study for safety concerns. This
may explain why the baseline calcium levels looked simi-
lar between groups. However, with no change for PTH
in the placebo group after 6 months, our reduction of
PTH in the vitamin D group does appear to be related
to vitamin D repletion. National Health and Nutrition
Examination Survey (NHANES) data have demonstrated
that PTH is associated with CRP [40]. We found that
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PTH also was associated with hsCRP, and selecting for
patients with hsCRP greater than 1 further strengthened
the effect of vitamin D3 on PTH.
Vitamin D directly affects the parathyroid gland,
and deficiency of vitamin D results in secondary
hyperparathyroidism. Hyperparathyroidism is strongly
associated with HF outcomes, with elevated PTH dir-
ectly related to both hospitalizations and mortality
[41, 42]. Additionally, PTH levels in heart failure pa-
tients are elevated compared to healthy adults [43],
suggesting that PTH dysregulation is a component in
the complex pathology of heart failure. Optimization
of PTH does not occur until 25(OH)D surpasses
40 ng/ ml [44].
Vitamin D status
Our results indicate that a vitamin D3 supplement of
10,000 IU per day effectively corrects vitamin D defi-
ciency in heart failure without evidence of adverse ef-
fects. Our dose-response is like other studies that
have used 10,000 IU of vitamin D3 daily, and a steady
state of serum 25(OH)D was reached by month 3
[22]. Further research is needed to evaluate if vitamin
D dosing guided by 25(OH)D levels would be equally
effective or superior, or if additional nutrient cofactors
would further improve patients’ response [15, 16].
Vitamin D deficiency increases the risk of all-cause
mortality, incident cardiovascular disease, and sudden
cardiac death in the general population [45]. Patients
with heart failure and vitamin D deficiency have an
almost 3-fold risk of death and 5-fold risk of sudden
cardiac death compared with those who are vitamin D
replete [6]. Vitamin D3 affects genetic expression related
to all cardiovascular cell types; it thereby helps regulate
cellular differentiation, apoptosis, hormone production,
and oxidative stress [46, 47]. The efficacy of vitamin D3
is related to its ability to provide enough substrate, so
the translation of vitamin D studies should involve serial
measurements of vitamin D status. Vitamin D repletion
is an appealing target therapy due to its numerous
physiological benefits for humans [15, 16].
Vitamin D activated to 1,25(OH)2D calcitriol is con-
sidered a pleiotropic hormone, and vitamin D receptors
occupy 2776 genome positions. Vitamin D directly af-
fects the expression of many genes, and a recent study
showed that improvement in vitamin D status after sup-
plementation results in correction of genetic expression
[47]. In this study, there was a 1.5 fold change in the ex-
pression of 291 genes with vitamin D supplementation
in vitamin D deficient healthy adults; 66 of those genes
had dramatic changes in expression [47]. Tripartite
Motive Containing 27 gene (TRIM27) and Early Growth
Response (EGR-1) gene among many others were down-
regulated; TRIM27 gene is associated with oxidative
stress, immunoglobin E mediated immunity among
others, and EGR-1 is linked to vascular health.
A recent meta-analysis demonstrated that supplemen-
tal vitamin D3 increases circulating 1,25(OH)2D levels
significantly, and its actions are mediated through vita-
min D receptors [48]. This is an important finding be-
cause circulating 1,25(OH)2D levels are associated with
better outcomes in end stage HF [49]. Cardiomyocytes,
immune cells, endocrine, and vascular smooth muscle
cells have vitamin D receptors and outcomes in HF are as-
sociated with circulating calcitriol levels [50–52]. These
receptors throughout the body also allow for onsite con-
version of1,25(OH)2D calcitriol and calcium-dependent
cellular processes, and high concentrations of calcitriol in
these cell types are likely necessary to trigger gene expres-
sion [51]. These key effects of vitamin D on post-
translation and non-genomic actions, such as transmem-
brane calcium transport, provide insight into the beneficial
mechanistic action of vitamin D on the cardiovascular sys-
tem [53].
Vitamin D deficiency, as defined by the Institute of
Medicine is <20 ng/ml for 25(OH)D levels, while insuffi-
ciency is generally considered to be 20–30 ng/ml [54].
New research suggests, however, that a circulating level of
20 ng/ml presents a 2-fold risk of secondary hyperpara-
thyroidism over levels greater than 30 ng/ml [55]. Elevated
PTH is associated with poor outcome in HF patients [56];
our findings demonstrate that vitamin D3 supplementa-
tion can markedly improve PTH concentrations at higher
circulating levels of 25(OH)D, further substantiating the
existing data showing that higher circulating 25(OH)D
concentrations helpmitigate hyperparathyroidism. Vitamin
D status is closely related to PTH status and 25(OH)D ap-
pears to suppress PTH across at all levels of 25(OH)D sta-
tus [57]. Additionally, it has become clear that the
extraskeletal benefits of vitamin D occur at higher circu-
lating blood levels of 25(OH)D; for example, respiratory
infection risks are reduced for those individuals with
25(OH)D in the range of 50 ng/ml or more [54]. For these
reasons, we chose a higher cutoff criterion for enrollment
than Institute of Medicine guidelines.
A question remains as to whether heart failure patients
require vitamin D3 treatment only in the cases of
25(OH)D < 20–30 ng/ml, or if all patients with heart
failure would benefit from supplementation despite nor-
mal circulating 25(OH)D levels. As of yet, evaluation of
vitamin D status is not routinely performed in heart fail-
ure. However, patients with chronic kidney disease pa-
tients do have routine monitoring in their guidelines
(56?). The case is made for class 1A indication for beta-
blocker use in patients with heart failure with reduced
ejection fraction even when the heart rate is not elevated
(26–27). In that situation, heart rate is a surrogate and
possibly imperfect marker for upregulation of
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sympathetic nervous system in heart failure. In our small
study, we found that monitoring 25(OH)D and subse-
quent repletion may have clinical merit with regard to im-
proved QOL and neurohormonal indices. Determining if
supplementation of vitamin D in all CHF patients without
regard to baseline status will require further research.
Inflammation
Vitamin D3 in our study did not appear to have a strong
impact on hsCRP as a whole, although men had an al-
most 2 mg/L reduction at 6 months. A prior study
showed that vitamin D3 given at 2000 IU per day for
nine months in heart failure improved cytokine profiles
[38], and both vitamin D and inflammation are related
in heart failure [55]. Vitamin D impacts several inflam-
matory pathways and acts to inhibit the activity of nu-
clear factor B activity, and by reducing interleukin 6,
interleukin 12, interferon C, and tumor necrosis factor
alpha production [38]. A recent review of vitamin D and
inflammation suggests that vitamin D possibly modestly
improves inflammation overall and that it may have
more anti-inflammatory effect with greater levels of in-
flammation in diseases such as end stage renal disease,
lupus, and tuberculosis, but also has effects on inflam-
mation in acute coronary syndrome [58]. Additionally,
inflammation related to vitamin D defiency is associated
with poor HF outcomes [59]. Both of our treatment
arms were equally matched in regard to statin usage at
baseline and had been on stable doses for at least
3 months, so this likely did not impact hsCRP in this
study. A recent review of inflammation and vitamin D
found that 6 out of 7 randomized clinical trials supple-
menting vitamin D found reductions in inflammatory
markers [60]. Our research was exploratory in nature
and was not powered to detect differences in hsCRP. Fu-
ture studies with marked elevation in inflammation
levels at baseline may be useful to further understand
the role of vitamin D3 for inflammation in HF.
Conclusions
Our study suggests that daily vitamin D3, used to replete
insufficient stores, may safely improve hormonal factors
in heart failure patients like 25(OH)D, BNP, and PTH as
well as inflammation. In addition to independent hor-
monal modulation, sufficient vitamin D3 repletion may
provide an important improvement in QOL as an adju-
vant treatment to appropriate guideline directed therapy.
Future considerations for research should additionally
measure 1,25(OH)2D levels and determine if 25(OH)D-
guided dosing is superior. Further work is needed to de-
termine if a provision of nutrient cofactors further en-
hance the effectiveness of vitamin D.
Additional files
Additional file 1: Data repository file. This file contains data for all
elements used in this research study. (XLS 62 kb)
Additional file 2: CONSORT checklist. (PPTX 2673 kb)
Abbreviations
1,25(OH)2D: 1,25-dihydroxyvitamin D; 25(OH)D: 25-hydroxyvitamin D;
ACE: Angiotensin Converting Enzyme; ARB: Angiotensin Receptor Blocker;
BMI: Body Mass Index; BNP: B-type Natriuretic Peptide; BP: Blood Pressure;
BUN: Blood Urea Nitrogen; CI: Confidence Interval; CO2: Carbon dioxide;
CPX: Cardiopulmonary status; CRP: C-Reactive Protein; EF: Ejection Fraction;
EGR1: Early Growth Response; HF: Heart Failure; HR: Heart Rate; hsCRP: High
Sensitivity C-reactive Protein; IU: International Units; KCCQ: Kansas City
Cardiomyopathy Questionnaire; LCZ696: Angiotensin-Neprilysin;
METS: Metabolic Equivalents; NHANES: National Health and Nutrition Survey;
NYHA: New York Heart Association; OUES: Oxygen Uptake Efficiency Slope;
PETCO2: Partial Pressure End Tidal Carbon Dioxide; PETO2: Partial Pressure
End Tidal Oxygen; PTH: Parathyroid Hormone; QOL: Quality of Life;
RER: Respiratory Exchange Ratio; SD: Standard Deviation; TRIM27: Tripartite
Motif Containing 27; V02: Oxygen Production; VCO2: Oxygen consumption;
Vol: Volume
Acknowledgments
We would like to acknowledge Ryan Mays, Ph.D., Joseph Knapp, MD,
Deborah Sybrant, PA and Heidi Boehm, RN.
Funding
1. Providence Saint Patrick Hospital Foundation grant (grant number
not applicable): funding went towards laboratory costs, data analysis,
research coordination. This funding body had no input in study
design, implementation, analysis, or publication.
2. International Heart Institute of Montana Foundation grant (grant
number not applicable): funding went towards research coordination.
This funding body had no input in study design, implementation,
analysis, or publication.
3. Experiment.com (grant number not applicable): funding went
towards research coordination, salary expenses. This funding body
had no input in study design, implementation, analysis, or
publication.
Availability of data and materials
All data generated and analyzed during this study are included in the
additional files of this published article [and its supplementary information
files].
Authors’ contributions
HM carried out the study design, research coordination, data collection,
statistical analysis, drafted and edited the manuscript. VC carried out the
study design, coordinated blinding, statistical analysis, assisted with data
collection, editing of the manuscript. BB carried out the study design,
provided patient physical exams, assisted with data collection, statistical
interpretation, drafting the manuscript. All authors read and approved the
final manuscript. The authors are all accountable for the integrity of the work
presented here, and will help answer any questions that arise related to
accuracy and integrity of the work presented.
Ethics approval and consent to participate
All patients provided written, informed consent to participate in this research
project. This study was performed in accordance with the Declaration of
Helsinki and its amendments. The trial was approved by the Providence
Saint Patrick Hospital Institutional Review Board August 8, 2012 (reference
number not applicable).
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Moretti et al. BMC Cardiovascular Disorders  (2017) 17:274 Page 10 of 12
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Providence Saint Patrick Hospital, 500 W. Broadway St, Missoula, MT 59802,
USA. 2International Heart Institute of Montana, 500 W. Broadway, Missoula,
MT 59802, USA. 3University of Montana, 32 Campus Drive, Missoula, MT
59812, USA.
Received: 26 May 2017 Accepted: 18 October 2017
References
1. Huffman MD, Berry JD, Ning H, Dyer AR, Garside DB, Cai X, et al. Lifetime
risk for heart failure among white and black Americans: cardiovascular
lifetime risk pooling project. J Am Coll Cardiol. 2013;14:1510–7.
2. Dunlay SM, Roger VL. Understanding the epidemic of heart failure: past,
present, and future. Curr Heart Fail Rep. 2014;11:404–15.
3. Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, Ik et al.
Forecasting the impact of heart failure in the United States: a policy statement
from the American Heart Association. Circ Heart Fail 2013; 6:606–619.
4. Weyland PG, Grant WB, Howie-Esquivel J. Does sufficient evidence exist to
support a causal association between vitamin D status and cardiovascular
disease risk? An assessment using Hill's criteria for causality. Nutrients. 2014;
6:3403–30.
5. Deda L, Yeshahay Y, Suds S, Cuerden M, Cerrney D, Sochett E et al.
Improvements in peripheral vascular function with vitamin D treatment in
deficienct adolescents with Type 1 Diabetes. Pediatr Diabetes. 2017. doi:
https://doi.org/10.1111/pedi.12595.
6. Pilz S, Marz W, Wellnitz B, Fahrleitner-Pammer A, Dimai HP, Boehm BO, et al.
Association of vitamin D deficiency with heart failure and sudden cardiac
death in a large cross-sectional study of patients referred for coronary
angiography. J Clin Endocrinol Metab. 2008;93:3927–35.
7. Witte KK, Byrom R, Gierula J, Paton MF, Jamil HA, Lowry JE, et al. Effects of
vitamin D on cardiac function in patients with chronic HF: the VINDICATE
study. J Am Coll Cardiol. 2016;67:2593–603.
8. Ameri P, Ronco D, Casu M, Denegri A, Bovio M, Menoni S, et al. High
prevalence of vitamin D deficiency and its association with left ventricular
dilation: an echocardiography study in elderly patients with chronic heart
failure. Nutr Metab Cardiovasc Dis. 2010;20:633–40.
9. Kim HW, Park CW, Shin YS, Kim YS, Shin SJ, Kim YS, et al. Calcitriol regresses
cardiac hypertrophy and QT dispersion in secondary hyperparathyroidism
on hemodialysis. Nephron Clin Prac. 2006;102:c21–9.
10. Shedeed SA, Vitamin D. Supplementation in infants with chronic congestive
heart failure. Pediatr Cardiol. 2012;33:713–9.
11. Zia AA, Komolafe BO, Moten M, Ahokas RA, JE MG, William Rosenberg E,
et al. Supplemental vitamin D and calcium in the management of African
Americans with heart failure having hypovitaminosis D. Am J Med Sci. 2011;
341:113–8.
12. Dalbeni A, Scaturro G, Degan M, Minuz P, Delva P. Effects of six months of
vitamin D supplementation in patients with heart failure: a randomized
double-blind controlled trial. Nutr Metab Cardiovasc Dis. 2014;24:861–8.
13. Amirlak I, Al Dhaheri W, Narchi H. Dilated cardiomyopathy secondary to
nutritional rickets. Ann Trop Paediatr. 2008;28:227–30.
14. Brown J, Nunez S, Russell M, Spurney C. Hypocalcemic rickets and dilated
cardiomyopathy: case reports and review of literature. Pediatr Cardiol. 2009;
30:818–23.
15. Heaney RP. Vitamin D–Baseline status and effective dose. N Engl J Med.
2012;367:77–8.
16. Heaney RP. Guidelines for optimizing design and analysis of clinical studies
of nutrient effects. Nutr Rev. 2014 Jan;72(1):48–54.
17. Keteyian SJ, Patel M, Kraus WE, Brawner CA, McConnell TR, Piña IL, et al.
Variables measured during cardiopulmonary exercise testing as predictors of
mortality in chronic systolic heart failure. J Am Coll Cardiol. 2006;47:752–6.
18. Heidenreich PA, Spertus JA, Jones PG, Weintraub WS, Rumsfeld JS, Rathore
SS, et al. Health status identifies heart failure outpatients at risk for
hospitalization or death. J Am Coll Cardiol. 2016;67:780–9.
19. DeBoland AR, Boland RL. Non-genomic signal transduction pathway of
vitamin D in muscle. Cell Signal. 1994;6:717–24.
20. Thomasset M, Parkes CO, Cuisinier-Gleizes P. Rat calcium-binding proteins:
distribution, development, and vitamin D dependence. Am J Phys. 1982;243:
E483–8.
21. Weishaar RE, Simpson RU. Involvement of vitamin D3 with cardiovascular
function. II. Direct and indirect effects. Am J Phys. 1987;253:E675–83.
22. Vieth R, Vitamin D. Supplementation, 25-hydroxyvitamin D concentrations,
and safety. Am J Clin Nutr. 1999;69:842–56.
23. Soto GE, Jones P, Weintraub WS, Krumholz HM, Spertus JA. Prognostic value
of health status in patients with heart failure after acute myocardial
infarction. Circulation. 2004;110:546–51.
24. Azarbal B, Hayes SW, Lewin HC, Hachamovitch R, Cohen I, Berman DS. The
incremental prognostic value of percentage of heart rate reserve achieved
over myocardial perfusion single-photon emission computed tomography
in the prediction of cardiac death and all-cause mortality: superiority over
85% of maximal age-predicted heart rate. J Am Coll Cardiol. 2004;44:423–30.
25. Udelson JE, Feldman AM, Greenberg B, Pitt B, Mukherjee R, Solomon HA,
et al. Randomized, double-blind, multicenter, placebo-controlled study
evaluating the effect of aldosterone antagonism with eplerenone on
ventricular remodeling in patients with mild-to-moderate heart failure and
left ventricular systolic dysfunction. Circ Heart Fail. 2010;3:347–53.
26. Ponikowski P, Voors A, Anker S Bueno H, John G. F. Andrew C, Coats J, et al.
2016 ESC guidelines for the diagnosis and treatment of acute and chronic
heart failure: the task force for the diagnosis and treatment of acute and
chronic heart failure of the European Society of Cardiology (ESC). Eur Heart
J 2016; 37:2129–2200.
27. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey Jr DE, Colvin MM, et al. 2017
ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the
Management of Heart Failure. J Am Coll Cardiol. 2017; https://doi.org/10.
1016/j.jacc.2017.04.025.
28. Masson S, Latini R, Anand IS, Barlera S, Angelici L, Vago T, et al. Prognostic
value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT
(valsartan heart failure trial). J Am Coll Cardiol. 2008;52:997–1003.
29. Jiang WL, HB G, Zhang YF, Xia QQ, Qi J, Chen JC, Vitamin D.
Supplementation in the treatment of chronic heart failure: a meta-analysis
of randomized controlled trials. Clin Cardiol. 2016;39:56–61.
30. Babar M, Haider SS, Mustafa G. Effects of vitamin D supplementation on
physical activity of patients with heart failure. Pak J Med Sci. 2016;32:1430–3.
10.12669/pjms.326.10714.
31. Li Q, Gardner DG. Negative regulation of the human atrial natriuretic
peptide gene by 1,25-dihydroxyvitamin D3. J Clin Endocrinol Metab. 2014;
99:2736–44.
32. Moser DK, Yamokoski L, Sun JL, Conway GA, Hartman KA, Graziano JA,
et al. Improvement in health-related quality of life after hospitalization
predicts event-free survival in patients with advanced heart failure. J Card Fail.
2009;15:763–9.
33. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al.
Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J
Med. 2014;371:993–1004.
34. Bischoff-Ferrari HA, Dietrich T, Orav EJ, FB H, Zhang Y, Karlson EW, et al.
Higher 25-hydroxyvitamin D concentrations are associated with better
lower-extremity function in both active and inactive persons aged > or =
60 y. Am J Clin Nutr. 2004;80:752–8.
35. Stewart JW, Alekel L, Ritland LM, Van Loan M, Gertz E, Genschel U. Serum
25-hydroxyvitamin D is related to indicators of overall physical fitness in
healthy postmenopausal women. Menopause. 2009;16:1093–101.
36. Witham MD, Crighton LJ, Gillespie ND, Struthers AD, McMurdo ME. The
effects of vitamin D supplementation on physical function and quality of
life in older patients with heart failure: a randomized controlled trial. Circ
Heart Fail. 2010;3:195–201.
37. Dobre D, Zannad F, Keteyian SJ, Stevens SR, Rossignol P, Kitzman DW, et al.
Association between resting heart rate, chronotropic index, and long-term
outcomes in patients with heart failure receiving β-blocker therapy: data
from the HF-ACTION trial. Eur Heart J. 2013;34:2271–80.
38. Abraham MR, Olson LJ, Joyner MJ, Turner ST, Beck KC, Johnson BD.
Angiotensin-converting enzyme genotype modulates pulmonary function
and exercise capacity in treated patients with congestive stable heart
failure. Circulation. 2002;106:1794–9.
39. Zhang Y, Deb DK, Kong J, Ning G, Wang Y, Li G, et al. Long-term
therapeutic effect of vitamin D analog doxercalciferol on diabetic
nephropathy: strong synergism with AT1 receptor antagonist. Am J Physiol
Renal Physiol. 2009;297:F791–801.
Moretti et al. BMC Cardiovascular Disorders  (2017) 17:274 Page 11 of 12
40. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R,
Vitamin D. Supplementation improves cytokine profiles in patients with
congestive heart failure: a double-blind, randomized, placebo-controlled
trial. Am J Clin Nutr. 2006;83:754–9.
41. Cheng SP, Liu CL, Liu TP, Hsu YC, Lee JJ. Association between parathyroid
hormone levels and inflammatory markers among US adults. Mediat
Inflamm. 2014;2014:709024.
42. Moslehi N, Shab-Bidar S, Mirmiran P, Hosseinpanah F, Azizi F. Determinants
of parathyroid hormone response to vitamin D supplementation: a
systematic review and meta-analysis of randomised controlled trials. Br J
Nutr. 2015;114:1360–74.
43. Schierbeck LL, Jensen TS, Bang U, Jensen G, Køber L, Jensen JE. Parathyroid
hormone and vitamin D–markers for cardiovascular and all-cause mortality
in heart failure. Eur J Heart Fail. 2011;13:626–32.
44. Sugimoto T1, Tanigawa T, Onishi K, Fujimoto N, Matsuda A, Nakamori S,
et al. Serum intact parathyroid hormone levels predict hospitalisation for
heart failure. Heart. 2009;95:395–8.
45. Kubiak GM, Kolaszko A, Nowalany-Kozielska E. Parathyroid hormone serum
concentration in Central European patients with non-ischemic heart failure
as a potential marker of disease severity and poor prognosis 2016; DOI:
https://doi.org/10.5603/EP.a2016.0057.
46. Ginde AA, Wolfe P, Camargo CA Jr, Schwartz RS. Defining vitamin D status
by secondary hyperparathyroidism in the U.S. population. 41. J Endocrinol
Investig. 2012;35:42–8.
47. Fiscella K, Vitamin D. Race, and cardiovascular mortality: findings from a
national US sample. Ann Fam Med. 2010;8:11–8.
48. Ramagopalan SV, Heger A, Berlanga AJ, Maugeri NJ, Lincoln MR, Burrell A,
et al. ChIP-seq defined genome-wide map of vitamin D receptor binding:
associations with disease and evolution. Genome Res. 2010;20:1352–60.
49. Hossein-Nezhad A, Spira A, Holick MF. Influence of vitamin D status and
vitamin D3 supplementation on genome wide expression of white blood
cells: a randomized double-blind clinical trial. PLoS One. 2013; https://doi.
org/10.1371/journal.pone.0058725.
50. Zittermann A, Ernst JB, Birschmann I, Dittrich M. Effect of vitamin D or
activated vitamin D on circulating 1,25-Dihydroxyvitamin D concentrations:
a systematic review and Metaanalysis of randomized controlled trials. Clin
Chem. 2015;61:1484–94.
51. Chen S, Glenn DJ, Ni W, Grigsby CL, Olsen K, Nishimoto M, et al. Expression
of the vitamin D receptor is increased in the hypertrophic heart.
Hypertension. 2008;52:1106–12.
52. Zittermann A, Schleithoff SS, Götting C, Dronow O, Fuchs U, Kuhn J,
Kleesiek K, Tenderich G, Koerfer R. Poor outcome in end-stage heart failure
patients with low circulating calcitriol levels. Eur J Heart Fail. 2008 Mar;10:
321–7.
53. Przybylski R, McCune S, Hollis B, Simpson RU, Vitamin D. Deficiency in the
spontaneously hypertensive heart failure [SHHF] prone rat. Nutr Metab
Cardiovasc Dis. 2010;20:641–6.
54. Pludowski P, Holick MF, Pilz S, Wagner CL, Hollis BW, Grant WB, et al.
Vitamin D effects on musculoskeletal health, immunity, autoimmunity,
cardiovascular disease, cancer, fertility, pregnancy, dementia, and mortality-
a review of recent evidence. Autoimmun Rev. 2013;12:976–89.
55. Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr. 2008:582S–6S.
56. Norman PE, Powell JT, Vitamin D. Cardiovascular Disease. Circ Res. 2014;114:
379–93.
57. Valcour A, Blocki F, Hawkins DM, Rao SD. Effects of age and serum 25-OH-
vitamin D on serum parathyroid hormone levels. J Clin Endocrinol Metab.
2012;97:3989–95.
58. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Bone
Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis 42:S1-
S202, 2003 (suppl 3).
59. Liu LC, Voors AA, van Veldhuisen DJ, van der Veer E, Belonje AM, Szymanski
MK, et al. Vitamin D status and outcomes in heart failure patients. Eur J
Heart Fail. 2011;13:619–25.
60. Cannell JJ, Grant WB, Holick MF, Vitamin D. inflammation.
Dermatoendocrinol. 2015;29(6):e983401.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Moretti et al. BMC Cardiovascular Disorders  (2017) 17:274 Page 12 of 12
